Anti Cd 20 Ocrevus denied for missing prior authorization by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for anti cd20 ocrevus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Requires Prior Authorization for Ocrevus — and What to Do

Ocrelizumab (Ocrevus) is a high-cost specialty biologic that UnitedHealthcare places on a prior-authorization (PA) requirement for all members. This means your prescriber must obtain advance approval from UHC before the infusion takes place — coverage is not automatic. A denial at this stage typically means the PA request was submitted without all required documentation, did not meet UHC's medical-necessity criteria as stated in their coverage policy, or was not submitted before the infusion was administered.

If a PA was submitted and denied on clinical grounds, that denial is a full adverse benefit determination and carries all appeal rights described below. If a PA was simply not submitted in advance, the process is different — and more urgent.

## Your Federal Appeal Rights

• PA denial = adverse benefit determination: Under ERISA §503 and ACA §2719, a denied prior authorization is subject to the same internal and external appeal rights as any other claim denial.
• Internal appeal: File within the deadline on your denial notice (commonly 180 days). For ongoing treatment, request an expedited internal review — UHC must respond within 72 hours for urgent pre-service appeals.
• External review: After a final internal adverse decision, file for independent external review within approximately four months. Expedited external review (72-hour decision) is available when the standard timeline would seriously jeopardize your health or treatment.
• Prospective (pre-service) expedited appeal: If the infusion has not yet occurred and delay would be clinically harmful, explicitly invoke your right to an expedited pre-service appeal at the time of filing.

## Concrete Steps and Timeline

1. If no PA was submitted: Have your neurologist's office submit a complete PA request immediately using UHC's specialty pharmacy or medical benefit PA portal. Include the full documentation package below with the initial submission to avoid a documentation-based denial. 2. If PA was denied on clinical grounds: Request the full denial letter and the UHC Medical Policy for ocrelizumab. 3. Identify exactly which PA criterion was not met — the denial must state this. 4. File an internal appeal (expedited if clinically urgent) addressing each unmet criterion with targeted documentation. 5. If the internal appeal is denied, file for external review before the four-month window closes.

## Documentation to Gather

• Diagnosis confirmation: Neurologist chart notes and MRI reports establishing MS diagnosis and subtype, with the correct ICD-10 code.
• Clinical disease activity or severity: Most recent relapse records, EDSS or equivalent functional assessment, and MRI progression data — supporting the clinical urgency of initiating or continuing ocrelizumab.
• Prior treatment history (relapsing forms): Complete, dated list of prior disease-modifying therapies with outcomes, showing the treatment history UHC's policy requires.
• Prescriber qualification: UHC typically requires that ocrelizumab be prescribed or managed by a neurologist. Confirm the prescriber's specialty is documented.
• Prescriber medical-necessity letter: A detailed letter from your neurologist addressing each criterion in UHC's PA policy, explaining why ocrelizumab is medically necessary, and referencing applicable AAN or ECTRIMS guidelines.
• Infusion site information: UHC may require that infusion occur at an approved site. Confirm the infusion center is in-network and include that information in the PA submission.

## Criteria-Mapping Structure

Obtain UHC's prior-authorization criteria for ocrelizumab (found in their coverage policy or PA requirements document). Map each:

| PA Criterion | Submitted Evidence | |---|---| | Confirmed MS diagnosis + subtype + ICD-10 | Neurologist note [date]; MRI [date] | | Disease activity / severity | EDSS [date]; MRI activity [date]; relapse log | | Prior DMT history (if required) | Therapy list with dates and outcomes | | Prescriber specialty | Neurologist specialty on prescriber NPI record | | Infusion site approval | Infusion center name, in-network status |

Submitting a complete, criteria-matched PA package on the first attempt is the most efficient path. If denied, the same mapping becomes the spine of your appeal.